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ABSTRACT
Objective To assess the effect of the UK Committee on
Safety of Medicines’ announcement in January 2005 of
withdrawal of co-proxamol on analgesic prescribing and
poisoning mortality.
Design Interrupted time series analysis for 1998-2007.
Setting England and Wales.
Data sources Prescribing data from the prescription
statistics department of the Information Centre for Health
and Social Care (England) and the Prescribing Services
Unit, Health Solutions Wales (Wales). Mortality data from
the Office for National Statistics.
Main outcome measures Prescriptions. Deaths from drug
poisoning (suicides, open verdicts, accidental
poisonings) involving single analgesics.
Results A steep reduction in prescribing of co-proxamol
occurred in the post-intervention period 2005-7, such
that number of prescriptions fell by an average of 859
(95% confidence interval 653 to 1065) thousand per
quarter, equating to an overall decrease of about 59%.
Prescribing of some other analgesics (co-codamol,
paracetamol, co-dydramol, and codeine) increased
significantly during this time. These changes were
associated with a major reduction in deaths involving co-
proxamol compared with the expected number of deaths
(an estimated 295 fewer suicides and 349 fewer deaths
including accidental poisonings), but no statistical
evidence for an increase in deaths involving either other
analgesics or other drugs.
Conclusions Major changes in prescribing after the
announcementofthewithdrawalofco-proxamolhavehada
marked beneficial effect on poisoning mortality involving
this drug, with little evidence of substitution of suicide
methodrelatedtoincreasedprescribingofotheranalgesics.
INTRODUCTION
For many years concerns have been expressed about
theextentoffatalpoisoningwiththeanalgesicco-prox-
amol(dextropropoxypheneincombinationwithpara-
cetamol), especially its use for suicide.
12Death occurs
largely because of the toxic effects of high levels of
dextropropoxyphene on respiration and cardiac
conduction.
34 The margin between therapeutic and
potentially lethal concentrations is relatively narrow.
5
Between 1997 and 1999 co-proxamol was the single
drug used most frequently for suicide in England and
Wales (766 deaths over the three year period), impli-
cated in nearly a fifth of all suicides from drug related
poisoning.
26
After the Medicines and Healthcare products Regu-
latory Agency reviewed the efficacy and safety profile
ofco-proxamol,theCommitteeonSafetyofMedicines
(CSM) advised in January 2005 that co-proxamol
should be withdrawn from use in the UK, the final
date of withdrawal being 31 December 2007.
78 The
committee also advised that during the intervening
period efforts should be made to move patients to sui-
table alternatives, although patients for whom this was
difficult could continue to receive the drug through
normal prescribing. This announcement had a major
effect during the withdrawal phase on prescribing in
England
910and in Scotland, where there was a benefi-
cial effect on suicides during 2005-6.
11
We evaluated the effect of the announcement of co-
proxamol withdrawal on prescribing and mortality
involvingco-proxamolandotheranalgesicsinEngland
andWales.Weinvestigateddeathsfromdrugpoisoning
thatreceivedaverdictofsuicideoranopenverdict,and
also those with a verdict of accidental death, some of
which may have been suicidal acts.
12 Substitution of
method is a potential concern where a common means
used for suicide becomes less available.
13 We therefore
investigated the possible effect of the withdrawal of co-
proxamol onthe prescribingofother analgesics andon
theiruseinsuicide.Ourmethodtakesaccountofunder-
lying trends in prescribing and deaths before the com-
mittee’s announcement.
METHOD
Prescriptions
We obtained data on prescriptions of co-proxamol and
ofco-codamol,codeine,co-dydramol,dihydrocodeine,
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cetamol, and tramadol (the analgesics most likely to be
used instead of co-proxamol) in England and Wales
from the prescription statistics department of the Infor-
mation Centre for Health and Social Care (England)
and the Prescribing Services Unit of Health Solutions
Wales (Wales), in the form of quarterly statistics for
1998 to 2007. We excluded preparations in the form
of liquids, suppositories, granules, and powders, and
also effervescent preparations, which are rarely used in
poisoning. Prescription data for Wales were not avail-
able for the first quarter of 1998, and therefore we
estimated values for this quarter with least squares
methods.
Deaths
To evaluate the effect of the withdrawal of co-proxa-
mol on suicide we used data on deaths that received a
suicideverdictandthoserecordedasdeathofundeter-
mined intent (open verdicts). In England and Wales, it
has been customary to assume that most injuries and
poisoningsof undetermined intent are cases where the
harm was self inflicted but there was insufficient evi-
dencetoprovethatthedeceaseddeliberatelyintended
to kill themselves.
1415
Quarterly information on deaths from drug poison-
ing(suicides,openverdicts,andaccidentalpoisonings)
involving co-proxamol alone, co-codamol, codeine,
co-dydramol, dihydrocodeine, NSAIDs, paracetamol,
and tramadol was provided by the Office for National
Statistics on the basis of death registrations during
1998-2007 in England and Wales. We restricted our
analyses to deaths involving single drugs or single
drugsandalcohol.Similardataweresuppliedforover-
all drug poisoning deaths receiving suicide, open, and
accidentalpoisoningverdicts,andforalldeathsreceiv-
ing suicide and open verdicts.
In assessing whether there has been any substitution
ofotheranalgesicsforco-proxamolamongselfpoison-
ing deaths we have combined mortality data for all the
other analgesics. We also examined trends in deaths
from poisoning with all drugs (suicide, open, and
accidental death verdicts) and deaths from all causes
(suicide and open verdicts only).
Statistical analyses
We analysed trends in prescribing and deaths with
Stata version 10.0.
16 We used interrupted time series
analysistoestimatechangesinlevelsandtrendsinpre-
scribing and deaths after the CSM announcement of
the withdrawal of co-proxamol. This method controls
for baseline level and trend when estimating expected
changes in the number of prescriptions (or deaths)due
to the intervention.
17
Specifically, we used segmented regression analysis
18
to estimate the mean quarterly number of prescriptions
and deaths that might have occurred in the post-inter-
vention period without the CSM announcement, and
the number of prescriptions and deaths that occurred
with the CSM announcement. The latter were obtained
from best fitted data lines from the regressions, and are
better estimates than taking the average of the actual
values. The end of 2004 was chosen as the point of inter-
vention.Thusourdata comprised 28 quarters in thepre-
intervention segment and 12 quarters in the post-inter-
vention segment. Slope and level regression coefficients
were used to estimate the average quarterly absolute dif-
ferences(usingthemidpointofthepost-interventionper-
iod, midway between quarter 2 and quarter 3 of 2006).
Preliminary analyses indicated some autocorrela-
tioninthedata,thereforetheCochrane-Orcuttautore-
gression procedure was used (rather than ordinary
linear regression) to correct for first order serially cor-
related errors. The Durbin Watson statistic of all final
modelswasclosetothepreferredvalueof2,indicating
that no serious autocorrelation remained.
RESULTS
Prescriptions
Prescription data for England and Wales showed a
steep reduction in prescription of co-proxamol in the
first two quarters of 2005, with further reductions
thereafter (fig 1).
Regression analyses indicated a significant decrease
in both level and slope in prescribing of co-proxamol
(appendixtable),suchthatthenumberofprescriptions
decreasedby anaverageof 859 (95% confidenceinter-
val [CI] 653 to 1065) thousand per quarter in the post-
intervention period (table 1). This change equated to
anoveralldecreaseofabout59%inthethreeyearpost-
intervention period, 2005 to 2007. We also noted sig-
nificant decreases in prescribing NSAIDS of an aver-
ageof1053(95%CI920to1186)thousandperquarter,
equating to an approximate 19% decrease overall for
2005to 2007; and fordihydrocodeineof an averageof
35 (95% CI 2 to 68) thousand per quarter, or approxi-
mately 6% overall for 2005 to 2007 (table 1).
Prescriptions for the other analgesics, apart from tra-
madol, increased significantly in the post-intervention
period (table 1). On the basis of mean quarterly esti-
mates, percentage increases over the 2005 to 2007 per-
iod were approximately 20% for co-codamol, 13% for
paracetamol,12%forco-dydramol,and8%forcodeine.
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P
r
e
s
c
r
i
p
t
i
o
n
 
i
t
e
m
s
 
d
i
s
p
e
n
s
e
d
p
e
r
 
q
u
a
r
t
e
r
 
(
0
0
0
s
)
0
2000
3000
4000
5000
6000
1000
1234
1998
1234
1999
1234
2000 2002 2003 2004 2005 2006 2007
1234
2001
123412341234123412341234
Co-proxamol
NSAIDs
Paracetamol
Co-codamol
Tramadol
Co-dydramol
Codeine
Dihydrocodeine
Co-proxamol withdrawal announced
Fig 1 | Prescriptions for analgesics dispensed in England and
Wales, 1998-2007.
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Mortality data for England and Wales showed a
marked reduction in suicide and open verdicts invol-
ving co-proxamol in the first quarter of 2005, which
persisteduntiltheendof2007(fig2andtable2).Before
2005 deaths due to co-proxamol alone accounted for
19.5% (95% CI 16.9 to 22.2) of all suicides by drug
poisoning, whereas between 2005 and 2007 they con-
stituted just 6.4% (5.2 to 7.5; table 2).
Regression analyses indicated a significant decrease
in both level and slope for deaths involving co-proxa-
mol which received a suicide or open verdict (appen-
dixtable),suchthatthenumberofdeathsdecreasedby
onaverage24(95%CI12to37)perquarterinthepost-
intervention period (table 1). This equated to an esti-
mated overall decrease of 295 (95% CI 251 to 338)
deaths, approximately 62%, in the post-intervention
period 2005 to 2007 compared with 1998 to 2004.
When deaths from accidental poisoning involving
co-proxamol were included, there was a mean quar-
terly decrease of 29 (95% CI 17 to 42) deaths, which
equated to an overall decrease of 349 (306 to 392)
deaths, approximately 61%, in 2005 to 2007 (table 1).
Therewerenostatisticallysignificantchangesinlevel
orslopeinthepost-interventionperiodfordeathsinvol-
ving the other analgesics, for those that received a sui-
cide or open verdict (mean quarterly change 5, 95% CI
−5 to 15) and when accidental poisoning deaths were
also included (mean quarterly change 4, −11 to 18).
There was a reduction during the post-intervention
period in deaths (suicide and open verdicts) involving
alldrugs(includingco-proxamolandotheranalgesics),
with the mean quarterly change between 2005 and
2007 being −31 (95% CI −66 to 3) deaths, but this
Table 1 |Changes in prescriptions and deaths from poisoning involving co-proxamol, other analgesics, and all drugs, in
England and Wales, 1998-2007, associated with the CSM announcement
Estimation of absolute effect during 2005 to 2007 of the CSM announcement*
Mean quarterly estimated
number without CSM
announcement †
Mean quarterly estimated
number with CSM
announcement †
Mean quarterly change
during 2005 to 2007 ‡
(95%CI) §
Prescriptions (thousands)
Co-proxamol 1465.1 605.7 −859 (−1065 to −653)
Co-codamol 2524.7 3024.6 500 (459 to 540)
Codeine 534.6 578.0 43 (31 to 55)
Co-dydramol 1018.2 1140.0 122 (99 to 145)
Dihydrocodeine 634.6 600.0 −35 (−68 to −2)
NSAIDs 5633.8 4581.0 −1053 (−1186 to −920)
Paracetamol 2947.0 3330.0 382 (268 to 497)
Tramadol 1130.1 1193.9 64 (−5 to 133)
Suicide, open
Co-proxamol 39 15 −24 (−37 to −12)
Other analgesics ¶ 39 44 5 (−5t o1 5 )
All drugs except co-proxamol and other analgesics 204 191 −13 (−34 to 8)
All drugs 283 252 −31 (−66 to 3)
All causes 1152 1130 −22 (−89 to 45)
Suicide, open, accidental
Co-proxamol 48 19 −29 (−42 to −17)
Other analgesics 56 60 4 (−11 to 18)
All drugs except co-proxamol and other analgesics 348 385 37 (−8t o8 2 )
All drugs 452 466 14 (−46 to 75)
*Using interrupted time series segmented regression analysis
18 where the intervention point is taken as the end of 2004 (the CSM announcement on
the withdrawal of co-proxamol, January 2005).
†Estimated for the midpoint quarter of 2005 to 2007. See appendix for method, equation (2) or (3).
‡Absolute difference of estimated number with CSM announcement and estimated number without CSM announcement, taken at the midpoint of the
post-intervention period, see appendix equation (4).
§95% confidence intervals (CI) taken from Stata results or calculated according to Zhang et al.
26
¶Co-codamol, codeine, co-dydramol, dihydrocodeine, NSAIDS, paracetamol, and tramadol.
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Fig 2 | Mortality in England and Wales from analgesic
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significance (table 1). The mean quarterly change in
the overall suicide rate (including open verdicts) was
−22 (95% CI −89 to 45). The substantial rise in deaths
involvingalldrugsinwhichasuicide,openoracciden-
tal verdict was reached (table 1) was largely due to an
increase in accidental deaths from drug misuse.
19
DISCUSSION
The rationale for co-proxamol being withdrawn in the
UK was that the efficacy and safety profile of the drug
was disadvantageous,
8 with co-proxamol being
involved in a large number of deaths from suicide
annually.
2 Thus, this measure was primarily aimed at
preventing suicides involving self poisoning with co-
proxamol. The data we have presented show that
after the announcement of the withdrawal of co-prox-
amol in January 2005 there was an immediate large
reduction in prescriptions, which during the period
2005-7 amounted to 59% fewer prescriptions than
expected on the basis of data for 1998-2004. This
decreasewasassociatedwitha62%reductionindeaths
from suicide related to co-proxamol (including open
verdicts), or an estimated 295 fewer deaths. Inclusion
ofaccidentaldeaths,someofwhichwerelikelytohave
been suicides,
12 increased the estimated reduction in
number of deaths to 349 over three years. This level
ofeffectwasconsistentwiththatfoundinScotlanddur-
ing 2005-6
11 and with benefits found with prescribing
restrictionsinothercountriesinEurope.
2021Somepre-
scribing continued during the withdrawal phase
because the CSM advice had allowed this.
78
Possiblesubstitutionofsuicidemethodmustbecon-
sideredinestimatingthe effect ofchangingavailability
ofaspecificmethodofsuicide.
1322Becausewithdrawal
of co-proxamol was associated with changes in pre-
scribing of other analgesics, an increase in use of
other analgesics for suicide might be expected.
Although prescribing of co-codamol, paracetamol,
and co-dydramol increased during 2005-7, analyses
of suicides and open verdict deaths involving other
analgesics combined indicated little evidence of such
substitution.Thisfindingisinkeepingwithlowertoxi-
city of most of these alternative drugs.Since poisoning
deaths with co-proxamol also often involve other sub-
stances,butco-proxamolisusuallythefatalagent,
5the
overallnumberofdeathspreventedbytheCSMinitia-
tivewasprobablyconsiderablygreaterthanthefigures
wehavereported,aswerestrictedouranalysistoover-
doses of single medicines.
An abrupt reduction in prescribing of NSAIDs
occurredshortlybeforetheannouncementofthewith-
drawal of co-proxamol, because of concerns about
COX 2 inhibitors.
23 However, NSAIDs are rarely a
direct acute cause of death, especially by suicide.
24
Overallsuicideandopenverdictdeathsdecreasedin
England and Wales during 2005 to 2007 but the
change was not statistically significant. Also the pro-
portionate decline was much greater and statistically
significant for co-proxamol. Thus underlying down-
wardtrendsinsuicidecannotaccountforthefullextent
of the decrease in co-proxamol related deaths.
The results of this study provide an example of how
the actions of regulatory authorities based on risk
assessment of drugs can have an important public
health function, as has also been found for measures
restricting pack sizes of analgesics sold over the
counter.
24
Strengths and limitations
We used national data to evaluate the effect of the
announcement of withdrawal of co-proxamol on pre-
scribinganddeaths.Werestrictedtheanalysestodeaths
involvingsingleanalgesicstoeliminatethepossiblecon-
tribution of other drugs to the deaths. We also investi-
gated possible substitution of method of suicide by
examiningprescribinganddrugpoisoningdeathsinvol-
ving other analgesics, and deaths receiving a coroner’s
verdictofaccidentalpoisoning,someofwhichmayhave
been intentional.
1225 We did not examine possible sub-
stitution with entirely different methods of suicide. The
mortality data we used were based on registrations
rather than actual dates of deaths, which might have
affected quarterly data but not the overall findings.
Table 2 |Suicide and open verdict deaths by all causes, and suicide, open verdict, and accidental deaths due to poisoning
by all drugs, co-proxamol alone, and other analgesics alone (or with alcohol) in England and Wales
All causes All drugs Co-proxamol alone† Other analgesics* alone†
Suicide,
open
Suicide,
open
Suicide, open,
accidental
Suicide,
open
Suicide, open,
accidental
Suicide,
open
Suicide, open,
accidental
1998 5347 1432 2250 298 (21) 354 (16) 207 (15) 283 (13)
1999 5241 1415 2298 298 (21) 359 (16) 208 (15) 280 (12)
2000 5081 1309 2147 296 (23) 345 (16) 175 (13) 229 (11)
2001 4904 1279 2181 268 (21) 322 (15) 200 (16) 262 (12)
2002 4762 1225 1984 217 (18) 265 (13) 182 (15) 237 (12)
2003 4811 1195 1844 196 (16) 226 (12) 166 (14) 237 (13)
2004 4883 1247 2007 204 (16 ) 249 (12) 168 (14) 232 (12)
2005 4718 1154 1927 70 (6) 86 (5) 183 (16) 238 (12)
2006 4513 979 1822 69 (7) 83 (5) 200 (20) 287 (16)
2007 4322 888 1852 53 (6) 63 (3) 151 (17) 209 (11)
*Co-codamol, codeine, co-dydramol, dihydrocodeine, NSAIDS, paracetamol, tramadol.
†Percentage of all drug poisoning deaths shown in brackets.
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series autoregression—controls for baseline level and
trend when estimating expected changes in the num-
berofprescriptions(ordeaths)duetotheintervention,
and is therefore preferable to simpler methods such as
a change in proportions before and after the inter-
vention which do not take long term baseline data
intoaccount.However,itshouldbenotedthattheesti-
matesoftheoveralleffectonprescriptionsandmortal-
ity involved extrapolation, which is inevitably
associated with uncertainty. Also the regression
method assumes linear trends over time, and the co-
proxamol prescribing data, in particular, had a poor
fit, resulting in large standard errors in the post-inter-
vention period. Estimates of the standard errors for
absolute mean quarterly changes in number of pre-
scriptions or deaths were determined exactly, includ-
ing the covariance of level and slope terms. Estimates
of percentage changes over the three year post-inter-
vention period, however, are point estimates and were
not determined with standard error calculations.
Therefore caution must be advised in interpreting
these percentages too literally.
Conclusions
The announcement of the withdrawal of co-proxamol
in the UK has had a substantial effect on prescribing
and on deaths from poisoning in England and Wales,
particularly suicides. This evidence, along with a simi-
lar finding for Scotland,
11 suggests that the UK initia-
tive has been an effective measure.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
In early 2005 the UK Medicines and Healthcare products Regulatory Agency announced
gradual withdrawal of co-proxamol because of its adverse benefit to safety ratio, especially
its use for intentional and accidental fatal poisoning.
Restriction of access to dangerous means for suicidal behaviour can reduce deaths from
suicide.
WHAT THIS STUDY ADDS
During the three year withdrawal phase (2005-7) prescription of co-proxamol in England and
Wales fell by 59%, with an increase in prescribing of some other analgesics.
The marked reduction in suicides and accidental poisonings involving co-proxamol during
this period, with no evidence of an increase in deaths involving other analgesics, suggests
that the initiative has been effective.
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